Drug
resistance
remains
the
greatest
challenge
in
improving
outcomes
for
cancer
patients
who
receive
chemotherapy
and
targeted
therapy.
Surmounting
evidence
suggests
that
a
subpopulation
of
cells
could
escape
intense
selective
drug
treatment
by
entering
drug-tolerant
state
without
genetic
variations.
These
(DTCs)
are
characterized
with
slow
proliferation
rate
reversible
phenotype.
They
reside
tumor
region
may
serve
as
reservoir
resistant
phenotypes.
The
survival
DTCs
is
regulated
epigenetic
modifications,
transcriptional
regulation,
mRNA
translation
remodeling,
metabolic
changes,
antiapoptosis,
interactions
microenvironment,
activation
signaling
pathways.
Thus,
targeting
regulators
opens
new
avenue
therapy-resistant
tumors.
In
this
review,
we
first
provide
an
overview
common
characteristics
regulating
networks
development.
We
also
discuss
potential
therapeutic
opportunities
to
target
DTCs.
Last,
current
challenges
prospects
DTC-targeting
approach
overcome
acquired
resistance.
Reviewing
latest
developments
DTC
research
be
essential
discovering
methods
eliminate
DTCs,
which
represent
novel
strategy
preventing
future.
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Апрель 17, 2024
Significant
advancements
have
been
made
in
hepatocellular
carcinoma
(HCC)
therapeutics,
such
as
immunotherapy
for
treating
patients
with
HCC.
However,
there
is
a
lack
of
reliable
biomarkers
predicting
the
response
to
therapy,
which
continues
be
challenging.
Cancer
stem
cells
(CSCs)
are
involved
oncogenesis,
drug
resistance,
and
invasion,
well
metastasis
HCC
cells.
Therefore,
this
study,
we
aimed
create
an
mRNA
expression-based
stemness
index
(mRNAsi)
model
predict
immunotherapy.
Cancer-associated
fibroblasts
(CAFs)
are
a
diverse
stromal
cell
population
within
the
tumour
microenvironment,
where
they
play
fundamental
roles
in
cancer
progression
and
patient
prognosis.
Multiple
lines
of
evidence
have
identified
that
CAFs
critically
involved
shaping
structure
function
microenvironment
with
numerous
functions
regulating
behaviours,
such
as
metastasis,
invasion,
epithelial-mesenchymal
transition
(EMT).
can
interact
extensively
cells
by
producing
extracellular
vesicles
(EVs),
multiple
secreted
factors,
metabolites.
Notably,
CAF-derived
EVs
been
critical
mediators
therapy
resistance,
constitute
novel
targets
biomarkers
management.
This
review
aimed
to
summarize
biological
detailed
molecular
mechanisms
mediating
resistance
chemotherapy,
targeted
agents,
radiotherapy,
immunotherapy.
We
also
discussed
therapeutic
potential
clinical
management,
thereby
providing
strategy
for
enhancing
efficacy
improving
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(13), С. 10910 - 10910
Опубликована: Июнь 30, 2023
Cancer
remains
a
leading
cause
of
death
globally,
and
its
complexity
poses
significant
challenge
to
effective
treatment.
stem
cells
their
markers
have
become
key
players
in
tumor
growth
progression.
CD133,
marker
various
cancer
types,
is
an
active
research
area
as
potential
therapeutic
target.
This
article
explores
the
role
CD133
treatment,
beginning
with
overview
statistics
explanation
markers.
The
rise
discussed,
including
structure,
functions,
occurrence
different
types.
Furthermore,
covers
target,
focusing
on
gene
therapy,
immunotherapy,
approaches
affect
expression.
Nanoparticles
such
gold
nanoparticles
nanoliposomes
are
also
discussed
context
CD133-targeted
therapy.
In
conclusion,
promising
target
for
As
this
progresses,
it
hoped
that
therapies
will
offer
new
treatment
options
patients
future.
Cancer Research,
Год журнала:
2023,
Номер
83(13), С. 2096 - 2104
Опубликована: Июль 5, 2023
Abstract
Use
of
immunotherapy
in
recent
years
has
revolutionized
cancer
treatment
for
certain
types
cancers.
However,
the
broad
utility
is
limited
because
there
are
still
many
that
do
not
respond
effectively.
Failure
a
to
due,
at
least
part,
its
phenotypic
plasticity,
feature
established
by
stem
cells
(CSC)
and
their
associated
microenvironments.
This
article
discusses
current
understanding
CSC-mediated
immune
evasion
provides
prospective
view
on
how
researchers
can
better
understand
overcome
intrinsic
privilege
CSCs
extrinsic
immune-suppressive
microenvironment
shaped
them.
Drug
resistance
remains
the
greatest
challenge
in
improving
outcomes
for
cancer
patients
who
receive
chemotherapy
and
targeted
therapy.
Surmounting
evidence
suggests
that
a
subpopulation
of
cells
could
escape
intense
selective
drug
treatment
by
entering
drug-tolerant
state
without
genetic
variations.
These
(DTCs)
are
characterized
with
slow
proliferation
rate
reversible
phenotype.
They
reside
tumor
region
may
serve
as
reservoir
resistant
phenotypes.
The
survival
DTCs
is
regulated
epigenetic
modifications,
transcriptional
regulation,
mRNA
translation
remodeling,
metabolic
changes,
antiapoptosis,
interactions
microenvironment,
activation
signaling
pathways.
Thus,
targeting
regulators
opens
new
avenue
therapy-resistant
tumors.
In
this
review,
we
first
provide
an
overview
common
characteristics
regulating
networks
development.
We
also
discuss
potential
therapeutic
opportunities
to
target
DTCs.
Last,
current
challenges
prospects
DTC-targeting
approach
overcome
acquired
resistance.
Reviewing
latest
developments
DTC
research
be
essential
discovering
methods
eliminate
DTCs,
which
represent
novel
strategy
preventing
future.
